Tudor Investment Corp
AKBA icon

Tudor Investment Corp’s Akebia Therapeutics AKBA Stock Holding History

Tudor Investment Corp’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-142,274
Closed -$188K – 2968
2024
Q3 		$188K Hold
142,274
– – ﹤0.01% 2548
2024
Q2 		$145K Hold
142,274
– – ﹤0.01% 2186
2024
Q1 		$260K Hold
142,274
– – ﹤0.01% 1920
2023
Q4 		$176K Hold
142,274
– – ﹤0.01% 2216
2023
Q3 		$162K Hold
142,274
– – ﹤0.01% 2114
2023
Q2 		$130K Hold
142,274
– – ﹤0.01% 2278
2023
Q1 		$80K Hold
142,274
– – ﹤0.01% 2271
2022
Q4 		$82K Sell
142,274
-4,434
-3% -$1.39K ﹤0.01% 2231
2022
Q3 		$46K Hold
146,708
– – ﹤0.01% 2191
2022
Q2 		$52K Sell
146,708
-491
-0.3% -$206 ﹤0.01% 1963
2022
Q1 		$106K Buy
147,199
+134,622
+1,070% +$288K ﹤0.01% 1829
2021
Q4 		$28K Buy
+12,577
New +$34.3K ﹤0.01% 2285
2021
Q3 		– Sell
-51,044
Closed -$193K – 2413
2021
Q2 		$193K Sell
51,044
-127,826
-71% -$430K ﹤0.01% 1503
2021
Q1 		$605K Buy
178,870
+3,091
+2% +$11.1K 0.01% 1061
2020
Q4 		$492K Buy
+175,779
New +$513K 0.01% 957
2018
Q2 		– Sell
-21,105
Closed -$201K – 1024
2018
Q1 		$201K Buy
+21,105
New +$295K 0.01% 870
2017
Q3 		– Sell
-12,155
Closed -$175K – 1067
2017
Q2 		$175K Sell
12,155
-5,622
-32% -$71.3K 0.01% 910
2017
Q1 		$164K Sell
17,777
-1,951
-10% -$19K 0.01% 1261
2016
Q4 		$205K Buy
19,728
+1,318
+7% +$11.3K 0.01% 1216
2016
Q3 		$167K Sell
18,410
-388
-2% -$3.3K ﹤0.01% 1288
2016
Q2 		$141K Buy
18,798
+300
+2% +$2.62K ﹤0.01% 1476
2016
Q1 		$167K Buy
+18,498
New +$150K ﹤0.01% 1541

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Tudor Investment Corp's AKBA Position: Q4 2024 in Review

Tudor Investment Corp sold out of Akebia Therapeutics (AKBA) in Q4 2024, closing a stake of 142,274 shares — an estimated $188K sold.

Tudor Investment Corp first reported a position in AKBA in Q1 2016 and held it in 22 quarters. The position peaked at $605K in Q1 2021. 121 funds tracked by Wall St. Rank hold AKBA as of Q4 2024.

  • Tudor Investment Corp reported no remaining Akebia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Tudor Investment Corp sold 142,274 Akebia Therapeutics shares in Q4 2024, an estimated $188K.
  • Tudor Investment Corp first reported a position in Akebia Therapeutics in Q1 2016 and held it in 22 quarters.
  • Tudor Investment Corp's Akebia Therapeutics position peaked at $605K in Q1 2021.
  • 121 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2024.

Based on Tudor Investment Corp's 13F filing for Q4 2024, filed 14 Feb 2025.